Objectives/Hypothesis: Recent studies indicate that vestibular schwannomas (VSs) rely on phosphatidylinositol 3-kinase/AKT activation to promote cell proliferation and survival; therefore, targeting AKT may provide new therapeutic options. We have previously shown that AR42, a novel histone deacetylase inhibitor, potently suppresses VS growth in vitro at doses correlating with AKT inactivation. The objectives of the current study were translational: 1) to examine the end biologic effects of AR42 on tumor growth in vivo, 2) to validate AKT as its in vivo molecular target, 3) to determine whether AR42 penetrates the blood-brain barrier (BBB), and 4) to study the pharmacotoxicity profile of AR42.
INTRODUCTION
Vestibular schwannomas (VSs), intracranial tumors arising from Schwann cells of the eighth cranial nerve, are disease-defining neoplasms in patients with neurofibromatosis type 2 (NF2). This autosomal-dominant syndrome occurs because of the biallelic loss of the NF2 gene on chromosome 22, which encodes a tumor-suppressor protein named merlin (moesin, ezrin, and radixinlike protein). 1, 2 Although patients with germline NF2 gene mutations develop bilateral VS, unilateral sporadic tumors are more common (95%). Most VSs are histologically benign; however, they can cause sensorineural hearing loss, balance abnormalities, tinnitus, vertigo, facial paralysis, hydrocephalus, and even death because of their critical intracranial location. 3 Current treatment options are excision via craniotomy and/or stereotactic radiation therapy. Surgical risks include spinal fluid leaks, meningitis, intracranial hemorrhage, coma, and death, whereas use of stereotactic radiation raises concerns for malignant transformation and delayed-onset, radiation-induced skull base malignancies. 4, 5 Malignant VSs (triton tumors) are highly aggressive and uniformly lethal. 6 No medical therapies are currently approved by the U.S. Food and Drug Administration (FDA) for VS; therefore, the clinical impact of developing novel drug treatments is self-evident.
Normal, differentiated cells become quiescent upon sensing cell-cell contact. [7] [8] [9] At confluence, the NF2 gene product merlin is thought to be a critical regulator of this contact-dependent inhibition to proliferation, but mechanistic details regarding merlin's tumor-suppressor function remain elusive. 10, 11 Recent studies suggest that merlin links cell adhesion to transmembrane receptor signaling 12 by controlling the availability and function of growth-promoting receptors at the cell surface. 13 Merlin's interactions with adaptor proteins such as NHERF1/EBP50 (Na-H þ exchange regulatory factor 1; ezrin/radixin/moesin-binding protein of 50 kDa) 14, 15 may explain why numerous intracellular growth-promoting pathways such as phosphatidylinositol 3-kinase (PI3-kinase)/AKT, mitogen-activated protein kinase, p21 activated kinase/c-Jun N-terminal kinase, and others can be deregulated by merlin loss. 16 Deregulated AKT signaling is tumorigenic in many human malignancies. 17 A longstanding hypothesis in our laboratory has been that VSs also rely on aberrant PI3-kinase/AKT activation to promote cell proliferation and survival. Prior work has shown that the absence of merlin results in post-translational activation of the PI3-kinase/AKT pathway and that upstream inhibition of AKT phosphorylation using a 3-phosphoinositide-dependent protein kinase-1 (PDK1) inhibitor suppresses schwannoma growth. [18] [19] [20] Histone deacetylase (HDAC) inhibitors (HDACis), a novel class of antitumor agents, were initially thought to suppress tumor growth via chromatin remodeling and epigenetic effects. Phylogenetic studies, however, demonstrated that all four classes of HDACs preceded evolution of histones, 21 and more than 50 transcription factors, DNA repair enzymes, signal transduction mediators, chaperone proteins, and structural proteins have now been identified as HDAC substrates. 22 AR42 (formerly OSU-HDAC42; Arno Therapeutics, Parsippany, NJ) is a phenylbutyrate-derived HDACi that inhibits AKT downstream from PI3K and PDK1 through protein phosphatase 1-mediated AKT dephosphorylation. 23 We recently confirmed that AR42 suppresses schwannoma cell proliferation in vitro at doses correlating with AKT dephosphorylation, cell cycle arrest, and apoptosis. 24 The current in vivo work was designed to facilitate the transition of AR42 to human VS clinical trials. We sought to 1) examine the end biologic effects of AR42 on tumor growth in vivo, 2) validate AKT as an in vivo molecular target; 3) determine whether AR42 penetrates the bloodbrain barrier (BBB); and 4) study the pharmacotoxicity profile of AR42.
MATERIALS AND METHODS

Drug Compounds
Pharmaceutical-grade AR42 was provided by Arno Therapeutics, Inc. (Parsippany, NJ) through a materials transfer agreement.
Tissue Acquisition and Establishment of Schwannoma Cell Cultures
Longstanding institutional review board-approved protocols for the acquisition of surgically removed VS specimens are in place. VS specimens obtained from the operating room are placed in Dulbecco's Modified Eagle's Medium (DMEM) (Invitrogen, Carlsbad, CA) immediately after surgical resection and cut into fragments before implantation into immunodeficient mice. Mouse Nf2 À/À schwannoma cells are obtained from tumors that develop spontaneously in P0Cre; Nf2 flox/flox mice having conditional Nf2 inactivation in Schwann cells. 25 They are cultured on dishes coated with poly-D-lysine/laminin (Sigma-Aldrich, St. Louis, MO) and maintained in DMEM/10% fetal bovine serum containing 10 ng/mL recombinant human NRG1-b1/HRG1-b1 epidermal growth factor (EGF) domain (heregulin, R&D Systems, Minneapolis, MN) and 0.2 lM forskolin (Sigma-Aldrich).
Establishment of Schwannoma Xenografts/Allografts
Institutional Animal Care and Use Committee protocols for the establishment of mouse xenografts/allografts are in place. Severe combined immunodeficient (SCID-ICR; Harlan Laboratories, Indianapolis, IN) mice are anesthetized with inhalational isoflurane during implantation of cells or tissues. Nf2 À/À schwannoma allografts are then established by aseptically preparing one flank of each SCID mouse, suspending Nf2 À/À schwannoma cells in Matrigel (BD Biosciences, San Jose, CA), and injecting approximately 0.2 mL of cell suspension subcutaneously near the sciatic nerve (flank injection; Fig. 1A ). For implantation of VS specimens, an incision is made along one proximal thigh while the contralateral leg is left undissected as an internal control. The biceps femoris muscle and sciatic nerve are identified to implant VS tissues en bloc near the nerve.
Animal Experiments
AR42-containing rodent chow was generated by Research Diets, Inc. (New Brunswick, NJ) to deliver an approximate target dose of 25 mg/kg/d per mouse. Wild-type female FVB/N mice (The Jackson Laboratory, Bar Harbor, ME) were fed drugimpregnated rodent chow for pharmacotoxicology and drug-penetration studies; the female SCID-ICR mice were utilized for xenograft experiments. Control mice in all experiments received normal rodent diets (Teklad; Harlan Laboratories). Both drugtreated and control mice were checked weekly, and at each time point, the cages were cleaned and water ports were charged. The total amount of food in each cage was weighed, and the amount of food consumed during the previous week was calculated. Each mouse was weighed separately. The total chow consumed per cage was divided by the number of days between checks, and this value was then divided by the number of mice per cage to calculate the amount of mouse chow consumed per mouse per day. Multiplying by the concentration of drug per gram of food, the amount of drug consumed per mouse per day was derived.
AR42-Treated P0Cre Nf2 2/2 Schwannoma Allografts
P0Cre Nf2 À/À schwannoma cells (300,000 cells in 0.2 mL of a 25% Matrigel solution) were injected subcutaneously into one flank of each SCID mouse using an 18-gauge needle (Fig.  1A) . The contralateral leg was used as control. Starting on postimplantation day 3, the mice were divided into two groups: 1) control mice were fed normal rodent chow, and 2) treatment mice were fed drug-impregnated rodent chow formulated to deliver approximately 25 mg/kg AR42 daily. The mice were imaged at 14, 23, and 33 days following injection using a 9.4 T/ cm magnetic resonance imaging (MRI) scanner. Following the final imaging sequence, all mice were sacrificed; their flank tumors were harvested, fixed in 10% neutral buffered formalin, and embedded in paraffin. Five-micron tissue sections were obtained. Standard hematoxylin-and-eosin (H&E) staining was performed as well as immunostaining for cleaved caspase-3 (#9661L) and phosphoSer473-AKT (D9E, #4060) (both from Cell Signaling Technology, Danvers, MA). Negative controls were treated with the same immunostaining protocol, except without the primary antibody.
AR42-Treated Human VS Xenografts (Fig. 1A) VS xenografts were surgically established in SCID mice by using a flank incision. The contralateral nonoperated limb was used as an internal control. All animals were fed normal rodent diets until 1-month MRI scans were obtained for each mouse. Tumor volumes calculated from this set of images were used as baseline measurements. Subsequently, experimental animals were fed AR42-impregnated rodent chow formulated to deliver 25 mg/kg of drug per day for a total of 2 months, and control animals were fed normal diets. A second MRI scan was obtained 3 months postimplantation (i.e., after 2 months of drug treatment in the experimental group), and differences in tumor size were quantified volumetrically. Tumor explants were stained for p-AKT and cleaved caspase-3 using the same antibodies noted previously. Ki-67 immunostaining was also performed (Ki-67 Clone SP6 rabbit monoclonal antibody #RM-9106; Thermo Scientific, Rockford, IL). Negative controls were treated with the same immunostaining protocol, except without the primary antibody.
MRI Analysis
All imaged mice were anesthetized with 2.5% isoflurane mixed with 1 L/min carbogen and maintained with 1% to 1.5% isoflurane during imaging. They were placed prone on a temperature-controlled mouse bed and inserted into a 35-mmdiameter quadrature volume coil. The imaging was performed using a Bruker Biospin 94/30 magnet (Bruker Biospin, Karlsruhe, Germany). The respiration and temperature of the animals were monitored during the course of the experiment using a Small Animal Monitoring and Gating system (Model 1025; Small Animals Instruments, Inc., Stony Brook, NY). Axial T1-weighted (repetition time [TR] ¼ 1,500 msec, echo time [TE] ¼ 7.5 msec, RARE Factor ¼ 4, navgs ¼ 4) and T2-weighted rapid acquisition with relaxation enhancement (RARE) images (TR ¼ 4,200 msec, TE ¼ 12 msec, RARE Factor ¼ 8, navgs ¼ 4) were acquired over the entire region of the tumor. The acquisition parameters for both the T1-and T2-weighted multislice scans were as follows: field of view ¼ 30 mm Â 30 mm, slice thickness ¼ 1 mm, matrix size ¼ 256 Â 256. An expert observer delineated a region of interest (ROI) that included the tumor. This was manually outlined (software developed in-house) using the T1-and T2-weighted images to calculate tumor volumes (i.e., pixel size outlined ROI slice thickness).
AR42 Pharmacotoxicity Studies (Fig. 1B)
A total of 29 female FVB/N wild-type mice (14 control mice and 15 AR42-treated mice) were used for pharmacotoxicity studies. Blood-chemistry data were obtained from 14 untreated mice to establish strain-specific normal laboratory values. Eight AR42-treated mice were submitted for organ histology and blood chemistries after they had been dosed for 3 months with AR42. An additional seven AR42-treated mice were submitted for analysis after 6 months of oral AR42 dosing. For comparative normal histology, two control animals each (fed normal chow) also underwent survey organ histology at the 3-and 6month time points.
Clinical and Anatomic Pathology
Complete postmortem evaluations were performed on recently euthanized wild-type female FVB/N mice fed AR42impregnated chow or control rodent chow for 3 and 6 months. Body (prebleed) and selected postbleed organ weights were recorded. All tissues (including heart; trachea and lungs; thymus; aorta; kidney and urinary bladder; liver and gall bladder; spleen; pancreas; salivary glands; lymph nodes; gastrointestinal tract; ovaries and uterus; thyroid, adrenal and pituitary glands; sciatic nerve and brain; and skin with mammary gland and adipose tissue) were fixed in 10% neutral buffered formalin with the exception of the sternum, vertebral column with spinal cord, and rear legs, which were fixed in Decalcifier I (Surgipath, Richmond, IL) for 48 hours. These tissues were processed and embedded in paraffin. Sections (4 lm) were stained with H&E, and evaluated with an Olympus BX45 light microscope with attached DP25 digital camera (B & B Microscopes Ltd., Pittsburgh, PA). Representative images from heart, liver, muscle, kidney, and brain sections were collected.
Hematology and Blood-Chemistry Studies
Blood from recently euthanized wild-type female FVB/N mice fed AR42-impregnated chow or control rodent chow for appropriate durations was collected by percutaneous cardiac puncture. Complete blood counts with five-part white blood cell (WBC) differentials were performed on a portion of EDTA anticoagulated whole blood (FORCYTE auto-sampler 10; Oxford Science, Inc., Oxford, CT). Following coagulation of the remaining whole blood at room temperature for 30 minutes, the clotted blood was centrifuged at 3,000 rpm for 5 to 10 minutes at 4 C. Biochemical profiles (including alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, total protein, albumin, globulin, total bilirubin, blood urea nitrogen, creatinine, cholesterol, triglycerides, glucose, calcium, sodium, potassium, chloride, phosphorus, amylase, lipase, and creatine kinase) were performed on serum samples (VetACE; Alfa Wasserman, West Caldwell, NJ).
AR42 Pharmacokinetics and Disposition in Brain Tissues (Fig. 1B)
Three control and six AR42-treated female FVB/N wildtype mice were submitted for drug-penetration studies in plasma and normal brain tissue after 3 months of continuous oral dosing via AR42-fortified chow. Plasma AR42 levels were determined using a validated LC-MS/MS method (Cheng and Liu et al. [2006] , and Cheng and Jones [2007] , both AACR Annual Meeting Abstracts [www.aacrmeetingabstracts.org]), and AR42 levels in brain tissues were determined by adapting this method to brain tissue homogenates. Briefly, approximately 50 mg of the frozen mouse brain tissue was transferred to a 2-mL microcentrifuge tube, and 10 lL of internal standard solution (10 lg/mL hesperetin) was added. The solution was homogenized in an ice bath, and the homogenate was mixed with 200 lL of lysis buffer followed by centrifugation. The supernatant was extracted with 1 mL ethyl acetate, and the organic layer was evaporated to dryness. The residue was reconstituted in 100 lL 50% acetonitrile, and a 20 lL aliquot of supernatant was injected for LC-MS/MS analysis. The LC-MS/MS system was a Thermo TSQ Quantum triple quadrupole mass spectrometer equipped with an electrospray ionization source, a Shimadzu LC-20AD HPLC pump (Shimaduz Scientific Instruments, Columbia, MD), and an LC-20AC autosampler. The sample was separated on a Thermo Betabasic C8 column (50 Â 2.1 mm) with isocratic 80% methanol containing 0.2% formic acid at the flow rate of 0.2 mL/min. Finally, AR42 and the internal standard solution were detected by multiple reactions monitoring the following paired ion transitions: m/z 313.00 > 133.10 and m/z 303.10 > 153. 10 .
RESULTS
AR42 inhibits P0Cre Nf2 À/À schwannoma allografts in vivo at doses correlating with decreased AKT phosphorylation. SCID mice harboring P0Cre Nf2 À/À schwannoma allografts were orally treated with AR42impregnated rodent chow, targeting a dose of 25 mg/kg/ d. Both control and treated mice were imaged 14, 23, and 33 days following injection, and tumors were sized volumetrically. Between the first and third imaging time points, the mean increase in tumor volume for the control (untreated) group was 12,690% (95% confidence interval [CI]: 9,920% to 15,444%); the increase in tumor volumes for AR42-treated mice was 3,296% (95% CI: 829% to 5,762%) ( Fig. 2A and 2B ). This striking decrease in allograft growth rates for drug-treated tumors was statistically significant (P ¼ .001). Histopathology and immunohistochemistry were also performed in tumor explants for in vivo molecular target analysis. With fewer darkly staining, hyperchromatic nuclei, H&Estained sections demonstrated relaxed chromatin structure after AR42 treatment (Fig. 3A) . On average, fewer mitotic figures were also observed in AR42-exposed P0Cre Nf2 À/À schwannoma allografts (3 per high power field [HPF]) than in controls (5 per HPF). Immunohistochemistry found significant decreases in p-AKT staining in drug-treated animals ( Fig. 3B ) and increased cleavage of procaspase-3 ( Fig. 3C ) after AR42 exposure, suggesting AR42-induced apoptosis. Average cell counts for p-AKT labeling using four HPFs from each P0Cre schwannoma allograft found 41 cells labeled with p-AKT antibody versus nine cells for the AR42 treatment group. The analysis of cleaved caspase-3 found an average of eight labeled cells in control explants, whereas there were 19 cells labeled in the AR42 treated animals. Ki-67 staining (images not shown) was robust in both groups owing to the rapidly proliferating nature of this cell line. Differences in proliferative index for control versus treated implants were not discernable by the naked eye, even at 600Â magnification.
AR42 suppresses growth of human VS xenografts. SCID mice harboring human VS xenografts were orally treated with either control rodent food or AR42-impregnated rodent chow targeting a dose of 25 mg/kg/d. Representative MRI for each group is presented in Figure 4C . Four of 10 control VS xenografts grew during the 2-month imaging interval, three persisted (minimal decrease in size), and three tumors shrank (Fig. 4A) . Statistical analysis found a 6% mean increase in xenograft volume for the untreated group, with 95% CI of À10% to 22%. In the AR42-treated animals, nine of 10 xenografts shrank dramatically, and one implant persisted with minimal change in tumor size between scans (Fig. 4B) . A 28% mean decrease in tumor volume was observed with 95% CI of À45% to À12% change. This CI did not cross the zero point, indicating that tumor shrinkage could be expected with >95% confidence in AR42-treated implants. In addition, the CIs between control and treatment groups did not overlap, suggesting statistically significant differences between their means. Unpaired t test analysis confirmed that these differences between mean tumor volumes (þ6% in controls versus À28% for AR42 treatment) were statistically significant (P ¼ .006). Immunostaining for p-AKT, cleaved procaspase-3, and Ki-67 was performed on several tumor explants ( Fig. 5) , and qualitative examination of several randomly chosen HPFs from treated and control slides was completed. Overall, the immunostaining for all three antibodies was less dramatic than for P0Cre allografts. On average, VS controls had six p-AKT-labeled cells versus three labeled cells for AR42 treated VS xenografts (per HPF). Cleaved caspase-3 immunostaining was absent in the control VS explant slides and was sporadically found in the treatment group (one cell per 4 HPFs). Although there was only isolated cleaved caspase-3 staining for the AR42 treated group, a more dramatic decline in Ki-67 staining was seen in the drugtreated animals. The control tumor explants had seven labeled cells versus two labeled cells in the AR42 group (per HPF). Taken together, these data suggest that while both cell cycle arrest and apoptosis were observed in VS after AR42 exposure, the former is predominant.
Pharmacotoxicity studies in animals receiving AR42 over 3-and 6-month dosing schedules found no clinically overt abnormalities. After the first month, the cohort of AR42-treated FVB/N mice reliably ingested enough chow to achieve the targeted drug dose. All wild-type FVB/N mice gained weight, and veterinary staff noted normal social and grooming behavior during this study. Compared with controls ( Fig. 6A ), a small drop in weight was observed for mice in the AR42 treatment group, which recovered quickly after the first 7 to 10 days (Fig. 6B) .
Multiorgan histology in animals that received AR42 over 3-and 6-month dosing schedules found no clinically significant abnormalities. After euthanasia, gross and microscopic analysis of kidney, heart, skeletal muscle, and cerebral cortex specimens found no architectural differences between control and drug-fed mice (Fig. 7) . Nearly all mice fed AR42 had some centrilobular hepatocellular hypertrophy at 6 months, a finding not present at 3 months. Both control and AR42-treated mice demonstrated macroscopic evidence of cystic ovarian follicles, which are common findings in the reproductive tract of aged female mice and do not represent preneoplastic lesions. Two of seven AR42-treated mice demonstrated microscopic evidence of lymphoid depletion in the thymus at 6 months, which was not noted in the 3-month treatment group.
Hematology and blood chemistry studies in animals that received AR42 over 3-and 6-month dosing schedules found no clinically significant abnormalities. WBC counts (with differential), hemoglobin, hematocrit, platelet counts, kidney function studies, liver enzymes, and bilirubin were determined in control (wild-type) FVB/N mice, 3-month AR42-treated mice, and mice treated with AR42 for 6 months (Fig. 8A ). No significant differences were observed between controls and 3-month treated mice; however, mice treated with AR42 for 6 months had a lower WBC count than controls (Fig. 8B ). Analysis of WBC differentials found that this difference was accounted for by an absolute lymphopenia. Neutropenia was not observed, and all mice, including those housed outside the ultrasterile barrier facility, survived the study period without clinical evidence of infection.
Orally administered AR42 crosses the BBB. To validate AR42 as a potential treatment for intracranial neoplasms, BBB penetration assays were performed using six wild-type FVB/N mice treated for 3 months. These mice gained weight normally ( Fig. 9A ) and demonstrated no clinical evidence of toxicity. Although drugimpregnated rodent chow was formulated to deliver a daily dose of 25 mg/kg of AR42 per mouse, we found that the daily AR42 intake was variable, ranging from a minimum of 25.3 mg/kg/d to a maximum of 37.5 mg/kg/d. The average dose of AR42 for the entire 3-month experiment was 34.4 mg/kg/d (Fig. 9B ). Pharmacokinetic analysis found significant variability in the drug concentration for both plasma and brain tissue (Fig. 9C) ; however, AR42 was detectable in all brain-tissue specimens analyzed.
DISCUSSION
Recent evidence linking aberrant deacetylation of histone and nonhistone proteins to cell proliferation has
provided strong impetus for the development of HDACis as cancer therapeutics. Structurally diverse natural and synthetic inhibitors to the zinc-containing catalytic site of these enzymes have been isolated. Most HDACis in clinical development inhibit both class I and class II HDACs and fall into several broad groups based on chemical structure: 1) hydroxamic acids, such as trichostatin A, 2) cyclic tetrapeptides and the depsipeptides, 3) benzamides, 4) electrophilic ketones, and 5) aliphatic acid compounds such as phenylbutyrate and valproic acid. 26, 27 Normal cells seem relatively resistant to HDACi treatment, and tumor cells undergo growth arrest, cell differentiation, and/or cell death. [28] [29] [30] Postulated mechanisms of action for this class of novel drugs include modulation of gene expression through chromatin remodeling, 31 induction of p21-and p27-mediated cell cycle arrest, [32] [33] [34] [35] [36] [37] [38] [39] [40] inhibition of the molecular chaperone protein HSP90, [41] [42] [43] [44] disruption of aggresomemediated protein degradation, 45 cytoskeletal disruption due to abnormal tubulin assembly, 46-50 induction of programmed cell death, 51-55 disruption of intracellular signal transduction, 23, [56] [57] [58] [59] [60] induction of oxidative injury, [61] [62] [63] and inhibition of angiogenesis. [64] [65] [66] [67] [68] [69] [70] AR42 (OSU-HDAC42; Arno Therapeutics) is a highpotency phenylbutyrate-derived HDACi that suppresses tumor growth, at least in part, by reshuffling protein phosphatase-1, which then results in downstream AKT dephosphorylation/inactivation. 23 We have recently confirmed that AR42 potently inhibits primary VS (inhibitory concentration 50% [IC 50 ] % 500 nM) and Nf2 À/À murine schwannoma (IC 50 % 250 nM) cell growth at doses correlating with decreases in p-AKT. 24 Total AKT protein levels remained unchanged in that study, suggesting that HDACi therapy did not alter AKT gene expression through epigenetic effects. Also, stable total Figure 4 were excised after the final magnetic resonance imaging sequence, fixed in formalin, and paraffin embedded. Immunostaining performed for phospho-Ser473-AKT revealed an approximately 50% decline in p-AKT staining for AR42-treated tumors versus control sections. Likewise, Ki-67 labeling revealed that AR42 treatment caused an approximately 50% decrease in the proliferative index. Staining sections with cleaved caspase-3 antibody was performed to evaluate apoptosis. AR42-treated tumors had modestly more cleaved caspase-3 positivity compared to control tumors, but the labeling was sparse.
AKT protein levels in schwannoma cells indicated that
HDACi-mediated acetylation of lysine residues on molecular chaperones such as HSP90 did not result in targeting AKT for degradation. [71] [72] [73] [74] [75] 24 Several groups have shown that post-translational activation of the PI3-kinase/AKT pathway is common in VSs and that AKT inhibition may be a viable treatment strategy. [18] [19] [20] Abnormal PI3-kinase/AKT activation has been found in both NF2-associated and sporadic schwannoma cells but not in primary human Schwann cells. 18, 76 NF2/merlin deficiency in VSs activates AKT signaling by several distinct but potentially complementary mechanisms. First, merlin helps mediate contact-dependent inhibition of growth 12 by controlling the availability and function of several cell surface receptors 13 such as the EGF receptor, ErbB2, and the platelet-derived growth factor receptor. 14, 15 Through its interactions with adaptor proteins such as NHERF1, 14, 15 merlin may facilitate context-dependent receptor signaling. 12, 14, 16, 76, 77 Second, Rong et al. have demonstrated that the NF2 gene product merlin can inhibit AKT activation by binding PI3kinase enhancer long isoform (PIKE-L). 78 PIKE-L is a guanosine triphosphatase that normally couples PI3-kinase to metabotropic glutamate receptors. 79 The binding of normally functioning merlin to PIKE-L prevents this protein's association with and activation of PI3K. Third, direct AKT-merlin interactions may contribute to abnormal AKT activation in schwannomas. [80] [81] [82] Once activated, AKT can target downstream modulators of apoptosis such as GSK3b, insulin receptor substrate-1, phosphodiesterase-3B, Bcl-2-associated death promoter (BAD) protein, caspase-9, Forkhead proteins, NF-jB, mammalian target of rapamycin (mTOR), nitric oxide synthase, Raf protein kinase, and BRCA1. AKT phosphorylation of BAD and the Forkhead transcription factors FKHR/FKHRL1 promotes their binding to 14-3-3 proteins and sequestration within the cytoplasm, rendering them inactive. [83] [84] [85] AKT can directly phosphorylate and inhibit caspase-9, a mediator of intrinsic apoptosis. 86 AKT also activates I-jB kinases, which phosphorylate I-jB and target this protein for degradation; this action frees NF-jB from I-jB-mediated cytoplasmic sequestration and permits NF-jB nuclear translocation, where it promotes transcription of prosurvival genes. 87 AKT prevents nuclear accumulation of bcatenin by phosphorylating and inhibiting its upstream regulator GSK3b. 88 b-catenin, part of the Wnt signaling pathway, is normally phosphorylated by GSK3b and targeted for degradation; however, GSK3b inhibition allows b-catenin to build up in the cytoplasm, translocate into the nucleus, and interact with the TCF/LEF family of transcription factors to initiate expression of antiapoptosis genes. AKT also phosphorylates and inactivates tuberin (TSC2), which results in the downstream activation of mTOR (normally inhibited by the TSC1/TSC2 complex). 89 mTOR activation increases protein synthesis by simultaneously activating p70 ribosomal protein S6 kinase (p70S6K) and inhibiting the translational repressor 4E-binding protein 1 (4E-BP1). 90, 91 AKT activation also can foster tumor growth by promoting cell cycle progression. First, GSK3b phosphorylates cyclin D1 and targets it for proteasomal degradation; thus, AKT-mediated inhibition of GSK3b promotes the stability of cyclin D1. 92 Second, AKT inhibits the transcription of and/or promotes degradation of p27 Kip1 , a CDK inhibitor that blocks the activity of the G1 and S-phase complexes cyclin E-CDK2, cyclin D-CDK4, and cyclin A-CDK2. AKT phosphorylates the FOXO Forkhead transcription factors, sequestering them in the cytoplasm and blocking FOXO-mediated transcription of p27 Kip1 . 93 AKT also directly phosphorylates p27 Kip1 , causing p27 Kip1 to be retained in the cytosol, 94 where it can undergo E3 ubiquitin ligase-mediated degradation. 95 Third, AKT activation may inhibit p53-mediated cell cycle checkpoints through phosphorylation and sequestration of p21 cip1/waf1 and through MDM2-mediated inhibition of p53. 96, 97 AKT phosphorylation of murine double minute 2 (MDM2) on serine 166 and serine 186 is necessary for MDM2 translocation into the nucleus, where it promotes p53 degradation. 97, 98 AKT also phosphorylates p21 cip1/waf1 at threonine 145, resulting in cytoplasmic localization. 98, 99 Finally, PI3-kinase/AKT inhibition has been shown to promote G2/M arrest in several models. 100 This effect may be mediated by AKT phosphorylation of BRCA1 (breast cancer type 1 Fig. 6 . Long-term AR42 dosing in mice achieved the targeted daily drug dose and did not affect weight gain. Wild-type female FVB/N mice were fed either normal or AR42 chow for 3 to 6 months. Both (A) control mice and (B) AR42-fed mice gained weight at comparable rates. A small weight drop was initially observed in the AR42 group when chow feeding was initiated, but this weight loss recovered rapidly. susceptibility protein) 101 or through Chk1, a kinase that inhibits the CDK-activating protein cdc25. 102 The antiproliferative effects of HDACi therapy are known to be drug specific, cell-type dependent, and con-text specific. 103 Our previous in vitro results found that IC 50 doses of AR42 preferentially caused cell cycle arrest in cultured human schwannomas, whereas increased doses and prolonged drug treatment resulted in Fig. 7 . AR42 was well tolerated with no clinically significant abnormalities in organ tissue histology identified during 6 months of oral dosing. The FVB/N mice described in Figure 6 were analyzed for histopathology across multiple organs. Shown are representative sections from the cerebral cortex, cardiac muscle, skeletal muscle, kidney, and liver. Mice fed AR42 chow for 3 months showed no detectable differences relative to control mice. Mice treated with AR42 for 6 months displayed centrilobular hepatocellular hypertrophy, a common adaptive response to xenobiotics.
apoptosis. 24 Based on these data, we hypothesized that prolonged AR42 exposure in vivo would result predominantly in apoptosis. The current study found this to be the case only for the more rapidly growing murine schwannoma implants, but human VS xenografts primarily underwent cell cycle arrest. AR42 suppressed tumor growth at doses correlating with decreased AKT phosphorylation in both sets of schwannoma grafts but more dramatically so in the Nf2 À/À murine schwannoma allografts. Also, analysis of cleaved caspase-3 immunostaining found clear evidence of apoptosis in AR42treated Nf2 À/À schwannoma allografts. In contrast, the antiproliferative effects of AR42 in VS xenografts appeared to involve primarily cell cycle arrest and only a minimal increase in apoptosis. Decreased Ki-67 and increased cleaved caspase-3 immunostaining were both observed, but the former was more apparent.
To experimentally determine whether AR42 is truly cytostatic or cytotoxic to VSs, a dedicated in vivo timecourse study looking at intracellular cell death mechanisms after varying periods of drug exposure needs be performed using an animal model. Another, perhaps more informative, approach would be to perform a phase 0 human clinical trial looking at intratumoral drug concentrations and molecular endpoints in patients asked to ingest AR42 for several weeks before planned surgical Fig. 8 . Mice fed AR42 for 6 months showed mild lymphopenia. FVB/N mice treated with AR42 for 3 and 6 months underwent hematology and blood chemistry analyses. (A) No significant differences were observed between control mice and mice fed AR42 for 3 months. Mice treated with AR42 for 6 months had lower white blood cell (WBC) counts than controls. Data are shown as the mean value with 95% confidence intervals. (B) Differential WBC analysis showed that the low WBC counts seen in 6-month AR42-fed mice were because of an absolute lymphopenia. Data are again shown as the mean value with 95% confidence intervals. NE# ¼ neutrophil number; LY# ¼ lymphocyte number; HB ¼ hemoglobin; HCT ¼ hematocrit; PLT ¼ platelets; BUN ¼ serum urea nitrogen; CREAT ¼ creatinine; GLU ¼ glucose; T PROT ¼ Total Protein; AST ¼ aspartate aminotransferase; ALT ¼ alanine aminotransferase; ALK PHOS ¼ alkaline phosphatase; TOT BILI ¼ total bilirubin. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] resection of their tumors. The latter would be meaningful as a prelude to phase 2 efficacy studies in humans.
Results from our murine pharmacotoxicity studies indicate that AR42 was well tolerated during both 3-month and 6-month dosing regimens. Histologic evaluation of heart, trachea and lungs, thymus, aorta, kidney and urinary bladder, liver and gall bladder, spleen, pancreas, salivary glands, lymph nodes, gastrointestinal tract, ovaries and uterus, thyroid, adrenal, and pituitary glands, sciatic nerve and brain, and skin with mammary gland and adipose tissues found no structural abnormalities. The only consistent morphologic lesion was mild hepatocellular hypertrophy, characterized histologically by cytoplasmic changes in the centrilobular to midzonal regions of the liver; this was only seen in mice fed AR42 for 6 months. Centrilobular hypertrophy is a common adaptive response to a range of stimuli, including pregnancy and lactation, hormonal fluctuations, dietary constituents, infections, and exposures to xenobiotics. It is typically caused by changes in mitochondria, smooth endoplasmic reticulum or peroxisomes, and a common cause is induction of the P450 microsomal system. Although most constitutively expressed P450s and other phase I metabolism enzymes have a predominant centrilobular localization, this hypertrophic response is not considered a toxic effect.
Hematologic and biochemical laboratory studies were performed in mice administered AR42 during 3-and 6-month regimens. Mice variably displayed mild biochemical abnormalities in ALT, AST, and GGT; they also displayed increased glucose, increased total bilirubin, increased phosphorus, increased triglycerides, decreased amylase, decreased calcium, decreased cholesterol, and increased or decreased creatine kinase. However, differences between treated and control mice were not statistically significant. Variability in laboratory values between mice is common; for example, GGT levels vary widely with values upwards of 14 U/L being found in seemingly ''normal'' mice. Moderately decreased WBC counts, primarily due to lymphopenia, was the only statistically significant difference between control mice and those fed AR42 for 6 months. This finding was not present at the 3-month treatment window, and importantly, no mice had overt signs of infection during Fig. 9 . Orally administered AR42 crosses the blood-brain barrier (BBB). FVB/N mice were fed AR42 for 3 months and BBB penetration assays were performed. (A) All mice in this study gained weight and displayed no clinical signs of toxicity. (B) The estimated mean AR42 dose was 34.4 mg/kg/d for this group. (C) AR42 was detected in the brains of all mice analyzed, but concentrations were highly variable.
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] either 3 or 6 months of AR42 treatment. In 2008, Sargeant and colleagues 104 dosed mice with AR42 for up to 18 weeks and reported similar findings: completely reversible leukopenia and anemia; increased serum AST, total bilirubin, albumin, and total protein; and decreased serum cholesterol, alkaline phosphatase, and potassium. Also consistent with our study, Sargeant et al. 104 also found no significant changes in body weight or other indicators of poor general health.
According to the National Institutes of Health Clinical Trials website (http://www.clinicaltrials.gov), there are currently only four active clinical trials targeting NF2-associated tumors. Three involve already FDAapproved agents such as lapatinib (GlaxoSmithKline; Research Triangle Park, NC) for VSs, bevacizumab/Avastin (Roche, Basel, Switzerland) for VSs/meningiomas, and sunitinib (Pfizer, New York, NY) for recurrent/progressive meningiomas; the fourth clinical trial looks at PTC299 (PTC Therapeutics; South Plainfield, NJ), a ''novel, orally administered, small molecule designed to inhibit the production of VEGF by targeting the posttranscriptional processes that regulate VEGF synthesis.'' Based on our current study results demonstrating schwannoma-specific preclinical efficacy, detailed molecular target analysis, and in vivo safety profiling, we propose that AR42 is an excellent candidate for translation to VS clinical trials. Discussions are currently underway with the pharmaceutical company licensing AR42 as well as the FDA to move in that direction. As AR42 was reliably detected in brain tissues of all orally dosed mice, its use as therapy for intracranial tumors is appropriate. We believe that with sustained oral dosing in human clinical trials, the in vitro IC 50 for VSs (approximately 500 nM) will likely be achieved.
CONCLUSION
AR42 suppresses schwannoma growth at doses correlating with AKT pathway inhibition. This orally bioavailable drug penetrates the BBB, is well tolerated, and represents a novel candidate for translation to human VS clinical trials.
